KemPharm® is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs.We employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules in order to improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create these new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug.
|Bank Name||KemPharm, Inc.|
|Chairman||Dr. Travis C. Mickle|
|CEO||Dr. Travis C. Mickle|